Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (18413)	1/30/1999 2:46:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

martin, Again I must disagree and in fact your very point would incriminate Viagra. The EU could have claimed that Pfizer never did adequate clinical trials covering the at risk group and used this as an excuse to deny Viagra approval but they did not. Had they done this, Viagra wouldn't have a leg to stand on and they would have been forced to produce Viagra studies on men with CVD. In essence they would have been forced to shoot themselves in the foot. Now as far as the NHS's position is concerned, it looks like their recommendations will win because the complainers will not be able to provide a list of other programs that should be cut so that the British government can fund Viagra for every Tom Dick and Harry who wants to be a stud. We are talking about practicality here. The proViagra bitchers can complain all they want. It's not going to change anything.